

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients

The ARISTOPHANES Study

Lip, Gregory Y H; Keshishian, Allison; Li, Xiaoyan; Hamilton, Melissa; Masseria, Cristina; Gupta, Kiran; Luo, Xuemei; Mardekian, Jack; Friend, Keith; Nadkarni, Anagha; Pan, Xianying; Baser, Onur; Deitelzweig, Steven

Published in:
Stroke

DOI (link to publication from Publisher):
[10.1161/STROKEAHA.118.020232](https://doi.org/10.1161/STROKEAHA.118.020232)

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Lip, G. Y. H., Keshishian, A., Li, X., Hamilton, M., Masseria, C., Gupta, K., Luo, X., Mardekian, J., Friend, K., Nadkarni, A., Pan, X., Baser, O., & Deitelzweig, S. (2018). Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients: The ARISTOPHANES Study. *Stroke*, 49(12), 2933-2944. <https://doi.org/10.1161/STROKEAHA.118.020232>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from vbn.aau.dk on: December 05, 2025

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients

The ARISTOPHANES Study

Gregory Y.H. Lip, MD; Allison Keshishian, MPH; Xiaoyan Li, PhD; Melissa Hamilton, MPH; Cristina Masseria, PhD; Kiran Gupta, PhD; Xuemei Luo, PhD; Jack Mardekian, PhD; Keith Friend, MD; Anagha Nadkarni, PhD; Xianying Pan, MS; Onur Baser, PhD; Steven Deitelzweig, MD

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) used multiple data sources to compare stroke/systemic embolism (SE) and major bleeding (MB) among a large number of nonvalvular atrial fibrillation patients on non-vitamin K antagonist oral anticoagulants (NOACs) or warfarin.

Methods—A retrospective observational study of nonvalvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin from January 1, 2013, to September 30, 2015, was conducted pooling Centers for Medicare and Medicaid Services Medicare data and 4 US commercial claims databases. After 1:1 NOAC-warfarin and NOAC-NOAC propensity score matching in each database, the resulting patient records were pooled. Cox models were used to evaluate the risk of stroke/SE and MB across matched cohorts.

Results—A total of 285 292 patients were included in the 6 matched cohorts: 57 929 apixaban-warfarin, 26 838 dabigatran-warfarin, 83 007 rivaroxaban-warfarin, 27 096 apixaban-dabigatran, 62 619 apixaban-rivaroxaban, and 27 538 dabigatran-rivaroxaban patient pairs. Apixaban (hazard ratio [HR], 0.61; 95% CI, 0.54–0.69), dabigatran (HR, 0.80; 95% CI, 0.68–0.94), and rivaroxaban (HR, 0.75; 95% CI, 0.69–0.82) were associated with lower rates of stroke/SE compared with warfarin. Apixaban (HR, 0.58; 95% CI, 0.54–0.62) and dabigatran (HR, 0.73; 95% CI, 0.66–0.81) had lower rates of MB, and rivaroxaban (HR, 1.07; 95% CI, 1.02–1.13) had a higher rate of MB compared with warfarin. Differences exist in rates of stroke/SE and MB across NOACs.

Conclusions—In this largest observational study to date on NOACs and warfarin, the NOACs had lower rates of stroke/SE and variable comparative rates of MB versus warfarin. The findings from this study may help inform the discussion on benefit and risk in the shared decision-making process for stroke prevention between healthcare providers and nonvalvular atrial fibrillation patients.

Clinical Trial Registration—URL: <https://www.clinicaltrials.gov/>. Unique identifier: NCT03087487. (*Stroke*. 2018;49:2933-2944. DOI: 10.1161/STROKEAHA.118.020232.)

Key Words: anticoagulants ■ apixaban ■ dabigatran ■ hemorrhage ■ rivaroxaban ■ stroke ■ warfarin

Stroke prevention is the principal priority in the management of atrial fibrillation (AF); in the presence of stroke risk factors, oral anticoagulants (OACs) are recommended to reduce this risk, as well as all-cause mortality.¹ Vitamin K antagonists (VKAs), such as warfarin, have been the standard

OAC for several decades; however, an increased rate of major bleeding (MB) was observed in AF patients when compared with no anticoagulant treatment or placebo.² In addition, warfarin treatment has a narrow therapeutic range, drug and food interactions, the requirement of regular blood test monitoring

Continuing medical education (CME) credit is available for this article. Go to <http://cme.ahajournals.org> to take the quiz.

Received February 7, 2018; final revision received September 10, 2018; accepted September 19, 2018.

From the Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (G.Y.H.L.); Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, United Kingdom (G.Y.H.L.); Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.); Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI (A.K.); Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb Company, Lawrenceville, NJ (X. Li, M.H.); Patient Health & Impact, Outcomes & Evidence, Pfizer, Inc, New York, NY (C.M., J.M.); US Health Economics and Outcomes Research, Bristol-Myers Squibb Company, Lawrenceville, NJ (K.G., A.N.); Patient Health & Impact, Outcomes & Evidence, Pfizer, Inc, Groton, CT (X. Luo); Worldwide Medical, Bristol-Myers Squibb Company, Lawrenceville, NJ (K.F.); Center for Observational Research and Data Sciences, Bristol-Myers Squibb Company, Lawrenceville, NJ (X.P.); Department of Internal Medicine, University of Michigan, Ann Arbor (O.B.); Department of Hospital Medicine, Ochsner Clinic Foundation, New Orleans, LA; and Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA (S.D.).

The online-only Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.020232>.

Correspondence to Gregory Y.H. Lip, MD, Price-Evans Professor of Cardiovascular Medicine, University of Liverpool, 6 West Derby St, Liverpool L7 8TX, United Kingdom. Email Gregory.Lip@liverpool.ac.uk

© 2018 The Authors. Bristol-Myers Squibb Company, and Pfizer Inc. *Stroke* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Stroke is available at <https://www.ahajournals.org/journal/str>

DOI: 10.1161/STROKEAHA.118.020232

of the international normalized ratio, and frequent need for dose adjustment.³

In recent years, 4 non-VKA OACs (NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, have been approved for stroke prevention in AF based on their noninferiority in efficacy and safety compared with warfarin in randomized controlled trials (RCTs).⁴ In addition, no anticoagulation monitoring is required, and fewer drug and food interactions are evident.⁵ NOACs have changed the landscape of OAC use for stroke prevention in AF,⁶ but there are some pharmacological differences among different NOACs, such as the mechanism of action, food effect, and renal clearance.⁵

There are no head-to-head clinical trials comparing the efficacy of NOACs versus other NOACs. However, indirect comparisons and network meta-analyses based on RCTs have demonstrated that NOACs have generally similar efficacy but varied safety profiles.^{7,8} Emerging observational studies have evaluated the effectiveness and safety among different NOACs in US clinical practice using single data sources, providing some evidence of the comparative effectiveness and safety between NOACs but with limited generalizability and a lack of a comprehensive evaluation on outcomes across various subgroups within nonvalvular AF (NVAF) patients.^{9,10}

Using multiple data sources, this ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) compared the rates of stroke/SE and MB and evaluated comparative rates across various subgroups among NVAF patients newly prescribed apixaban, dabigatran, rivaroxaban, or warfarin.

Methods

Data Sources

Authors will not be able to make their data available to other researchers because of restrictions specified in data licenses and data use agreements. However, the corresponding author is willing to share any nonproprietary information about analytical methods with any other researchers who want to reproduce the results or replicate the procedure if they have specific questions about the manuscript. This study was registered at URL: <https://www.clinicaltrials.gov> (Unique identifier: NCT03087487).

Data in this study were pooled from the US Centers for Medicare and Medicaid Services Medicare data and 4 commercial claims databases in the United States: the Truven MarketScan Commercial Claims and Encounter and Medicare Supplemental and Coordination of Benefits Database (MarketScan), the IMS PharMetrics Plus Database (PharMetrics), the Optum Clinformatics Data Mart (Optum), and the Humana Research Database (Humana)—which cover >180 million beneficiaries annually (~56% of the US population).

Centers for Medicare and Medicaid Services Medicare data contain medical and pharmacy claims from the 100% Medicare population enrolled in Part A, Part B, and Part D programs (medical and pharmacy coverage). Detailed descriptions for the 5 data sets, rationale for the pooling process, and our approaches to minimize potential patient record duplicates across data sources can be found in a previously published article and Document I in the [online-only Data Supplement](#).¹¹

Patient Selection

Patients with ≥1 pharmacy claim for apixaban, dabigatran, rivaroxaban, or warfarin between January 1, 2013, and September 30, 2015, (identification period) were selected. The first NOAC pharmacy claim date during the identification period was designated as the index date for patients with any NOAC claim(s). For those without a NOAC

claim, the first warfarin prescription date was designated as the index date. Patients were required to have an AF diagnosis on or before the index date and have continuous medical and pharmacy health plan enrollment for ≥12 months before the index date (baseline period).

Patients treated with any OAC within 12 months before the index date, with evidence of valvular heart disease, venous thromboembolism, transient AF (pericarditis, hyperthyroidism, thyrotoxicity), or heart valve replacement/transplant during the baseline period, with pregnancy during the study period, or with hip or knee replacement surgery within 6 weeks before the index date, were excluded. Additional exclusion criteria can be found in Figure I in the [online-only Data Supplement](#).

Outcome Measures

Outcome measures were time to first stroke/SE, including ischemic stroke, hemorrhagic stroke, and SE, and time to first MB, including gastrointestinal bleeding, intracranial hemorrhage, and MB at other key sites (Table I in the [online-only Data Supplement](#)).^{12,13} Outcomes were based on hospitalizations with stroke/SE or MB as the principal or first-listed diagnosis. The follow-up period was from the day after the index date to 30 days after the discontinuation date, switch date, death (only inpatient death for the commercial databases and all-cause death for Medicare database), end of continuous medical or pharmacy plan enrollment, or the end of study period (September 30, 2015), whichever occurred first. Additional details about patient selection and outcome measures can be found in Document I in the [online-only Data Supplement](#).

Statistical Methods

One-to-one propensity score matching (PSM) was conducted between NOACs and warfarin (apixaban versus warfarin, dabigatran versus warfarin, and rivaroxaban versus warfarin) and between the NOACs (apixaban versus dabigatran, apixaban versus rivaroxaban, and dabigatran versus rivaroxaban). Patients were matched 1:1 in each data set based on the propensity scores generated by logistic regression based on demographics, Charlson Comorbidity Index score,¹⁴ baseline bleeding and stroke/SE history, comorbidities, and baseline comorbidities (complete list of covariates in Table II in the [online-only Data Supplement](#)). Nearest neighbor matching method without replacement with a caliper of 0.01 was used to match the patients.¹⁵ The balance of covariates was checked based on standardized differences with a threshold of 10%.¹⁶ Study patients from the 5 datasets were pooled for analysis after ensuring cohorts were balanced.

After PSM, the rate of stroke/SE and MB in each PSM cohort was evaluated with Cox proportional hazard models with robust sandwich estimates.¹⁵ OAC treatment was included as the independent variable, and no other covariates were included in the model because the cohorts were balanced.

Subgroup Analyses

Subgroup analyses were conducted for the following subgroups within the matched cohorts: age strata (<65, 65–74, 75–79, and ≥80 years), sex, baseline CHA₂DS₂-VASC score (0–1, 2–3, and ≥4), baseline HAS-BLED score (<3 and ≥3), congestive heart failure, coronary artery disease, peripheral arterial disease, diabetes mellitus, renal disease, and prior stroke/SE. For the baseline CHA₂DS₂-VASC score subgroup, female patients without other stroke risk factors (ie, low risk) were assigned with a score of 0.¹⁷ In each subgroup, the balance of baseline characteristics between the treatment cohorts was evaluated. When the standardized difference was >10%, the covariate was included in the Cox proportional hazards model. In each subgroup analysis, the statistical significance ($P<0.10$) of the interaction between treatment and the specific subgroup(s) was evaluated.

As another set of subgroup analysis, PSM and Cox models were reducted to separately evaluate outcomes associated with each standard-dose NOAC (apixaban 5 mg, dabigatran 150 mg, rivaroxaban 20 mg) and lower-dose NOAC (apixaban 2.5 mg, dabigatran 75 mg, rivaroxaban 15 mg/10 mg) based on the index prescription dosage. Rematched cohorts included standard-dose NOAC versus

warfarin, lower-dose NOAC versus warfarin, standard-dose NOAC versus standard-dose NOAC, and lower-dose NOAC versus lower-dose NOAC.

Sensitivity Analysis

Three sensitivity analyses were conducted. First, a sensitivity analysis was conducted by restricting the follow-up period to 1 year to help balance the follow-up period between the cohorts. Second, multivariate Cox proportional hazard models were conducted on all patients meeting the eligibility criteria (without PSM but with all covariates previously used for propensity score estimation alternatively adjusted for in the Cox models). Third, we evaluated the rate of all-cause death for Medicare patients. In the Medicare data, death was obtained by validated Social Security records that include the date of death. The other databases do not include complete death information, so mortality was only evaluated using the Centers for Medicare and Medicaid Services Medicare data.

Because the core study herein does not involve the collection, use, or transmittal of individual identifiable data, institutional review board approval is not required. Both the data sets and the security of the offices where analysis was completed (and where the data sets are kept) meet the requirements of the Health Insurance Portability and Accountability Act of 1996.

Results

After applying the selection criteria, a total of 321 182 NVAf patients were identified, including 63 484 apixaban, 27 571 dabigatran, 103 477 rivaroxaban, and 126 650 warfarin patients (Figure I in the [online-only Data Supplement](#)). Before PSM, warfarin patients were the oldest and had the highest baseline CHA₂DS₂-VASC and HAS-BLED scores, followed by apixaban, rivaroxaban, and dabigatran patients. For apixaban, dabigatran, and rivaroxaban patients, 21% (2.5 mg), 15% (75 mg), and 24% (19% on 15 mg and 5% on 10 mg) had lower dosage regimens, respectively.

The unadjusted incidence rate of stroke/SE—including ischemic stroke, hemorrhagic stroke, and systemic embolism—was 1.3 (apixaban), 1.5 (dabigatran), 1.4 (rivaroxaban), and 2.2 (warfarin) per 100 person-years. The unadjusted incidence rate of MB was 3.5 (apixaban), 3.5 (dabigatran), 5.3 (rivaroxaban), and 6.3 (warfarin) per 100 person-years (Table II in the [online-only Data Supplement](#)).

After PSM, a total of 285 292 unique patients were included in the 6 matched cohorts: 57 929 apixaban-warfarin, 26 838 dabigatran-warfarin, 83 007 rivaroxaban-warfarin, 27 096 apixaban-dabigatran, 62 619 apixaban-rivaroxaban, and 27 538 dabigatran-rivaroxaban PSM pairs. Each cohort was matched separately; therefore, it is not appropriate to compare across the cohorts. The baseline characteristics of the matched populations are shown in Table 1 and Tables III and IV in the [online-only Data Supplement](#).

NOAC-Warfarin and NOAC-NOAC Comparisons

The Kaplan-Meier curves for cumulative incidence rates of stroke/SE and MB in the matched populations are shown in Figure 1A and 1B.

Compared with warfarin, apixaban (hazard ratio [HR], 0.61; 95% CI, 0.54–0.69), dabigatran (HR, 0.80; 95% CI, 0.68–0.94), and rivaroxaban (HR, 0.75; 95% CI, 0.69–0.82) were all associated with lower rates of stroke/SE (Figure 2A). All NOACs were associated with lower rates of hemorrhagic stroke, whereas

apixaban and rivaroxaban patients were associated with lower rates of ischemic stroke compared with warfarin.

Apixaban (HR, 0.58; 95% CI, 0.54–0.62) and dabigatran (HR, 0.73; 95% CI, 0.66–0.81) were associated with lower rates of MB compared with warfarin. Rivaroxaban (HR, 1.07; 95% CI, 1.02–1.13) was associated with a higher rate of MB compared with warfarin. All 3 NOACs were associated with a lower rate of intracranial hemorrhage compared with warfarin. Apixaban was associated with a lower rate (HR, 0.59; 95% CI, 0.54–0.66), and rivaroxaban was associated with a higher rate (HR, 1.25; 95% CI, 1.16–1.34) of gastrointestinal bleeding compared with warfarin.

Apixaban was associated with a lower rate of stroke/SE and MB compared with dabigatran (stroke/SE—HR, 0.69; 95% CI, 0.56–0.84; MB—HR, 0.77; 95% CI, 0.68–0.87) and rivaroxaban (stroke/SE—HR, 0.80; 95% CI, 0.71–0.91; MB—HR, 0.55; 95% CI, 0.51–0.59; Figure 2B). Dabigatran was associated with a lower rate of MB (HR, 0.70; 95% CI, 0.63–0.77) compared with rivaroxaban, with similar rates of stroke/SE (HR, 1.15; 95% CI, 0.96–1.37).

Subgroup Analyses

The results of the subgroup analyses on age strata, sex, and baseline CHA₂DS₂-VASC score, HAS-BLED score, congestive heart failure, coronary artery disease, peripheral arterial disease, diabetes mellitus, renal disease, and prior stroke/SE were generally consistent with the main results. A few significant interactions were evident.

The magnitude of stroke/SE risk reduction for apixaban versus warfarin was greater in patients aged 75+ than those with aged <75 ($P_{\text{int}}=0.049$). Significant interaction was also found when evaluating the comparisons in MB for dabigatran and rivaroxaban versus warfarin across age/sex/CHA₂DS₂-VASC score, with lower HRs observed in patients who were younger, male, and with lower baseline CHA₂DS₂-VASC scores (Figure 3A and 3B).

In the dose subgroup analysis, patients with lower- and standard-dose NOACs had very different baseline characteristics (Tables V through X in the [online-only Data Supplement](#)). After PSM, both lower- and standard-dose patients showed broadly consistent results to the main analysis (Figure 3).

In the 2 sensitivity analyses, the results were generally consistent with the main analysis. When evaluating mortality in the Medicare population, all NOACs were associated with a lower rate of mortality compared with warfarin, and apixaban was associated with a lower rate of mortality compared with dabigatran and rivaroxaban (Tables XI through XIII in the [online-only Data Supplement](#)).

Discussion

To our best knowledge, the ARISTOPHANES study is the largest retrospective observational study to date examining the risk of stroke/SE and MB among NVAf patients who initiated NOAC treatment. By pooling the Centers for Medicare and Medicaid Services Medicare and 4 large US national claims data sets, this study demonstrated that apixaban, dabigatran, and rivaroxaban were associated with lower rates of stroke/SE compared with warfarin, and the safety results varied across NOACs.

Table 1. Baseline Characteristics of Patients Prescribed Warfarin and NOACs After Propensity Score Matching

	Apixaban (N=57 929)	Warfarin (N=57 929)	Dabigatran (N=26 838)	Warfarin (N=26 838)	Rivaroxaban (N=83 007)
	Mean/%	Mean/%	Mean/%	Mean/%	Mean/%
Age	74.3	74.2	71.9	72.0	74.4
<65	17.5%	17.6%	23.6%	23.6%	14.9%
65–74	30.9%	31.0%	33.4%	34.0%	33.7%
75–79	18.1%	18.1%	17.9%	18.0%	19.4%
≥80	33.5%	33.3%	25.1%	24.4%	32.0%
Sex					
Male	54.1%	53.8%	58.8%	58.6%	55.1%
Female	45.9%	46.2%	41.2%	41.4%	44.9%
Baseline comorbidity					
CHA ₂ DS ₂ -VASC Score	3.7	3.7	3.4	3.4	3.7
0	3.6%	3.4%	5.4%	5.3%	2.9%
1	6.2%	6.1%	8.8%	8.8%	6.1%
2	14.5%	13.8%	16.9%	16.6%	14.6%
3	21.5%	22.0%	22.5%	22.8%	22.6%
4+	54.2%	54.7%	46.3%	46.5%	53.8%
HAS-BLED score*	3.0	3.0	2.7	2.7	2.9
0	2.9%	2.9%	4.5%	4.6%	2.5%
1	10.5%	10.6%	14.0%	14.0%	10.5%
2	25.3%	25.5%	29.1%	28.6%	26.7%
3+	61.4%	61.0%	52.3%	52.7%	60.3%
Congestive heart failure	28.5%	28.9%	24.5%	24.8%	27.8%
Diabetes mellitus	34.8%	34.7%	35.0%	35.1%	35.8%
Renal disease	23.0%	23.3%	16.2%	16.6%	20.4%
Stroke/SE	12.1%	12.3%	10.1%	10.3%	11.7%
Peripheral artery disease	19.3%	20.3%	15.6%	16.9%	19.0%
Coronary artery disease	46.2%	45.5%	40.5%	39.7%	44.3%
Dose of the index prescription					
Standard dose†	77.5%		84.6%		72.1%
Lower dose‡	22.5%		15.4%		27.9%
Follow-up time, d	200.4	246.9	236.4	246.1	246.9
Median	135	158	130	156	153

(Continued)

The results of this study add evidence to supplement results from clinical trials, where all the NOACs had non-inferior rates of stroke/SE and MB compared with warfarin.^{4,18–20} The results for apixaban versus warfarin were similar to the results of the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), wherein apixaban was superior to warfarin in preventing stroke/SE and in reducing the risk of MB.²⁰ In the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), dabigatran 150 mg was associated with a lower risk of stroke/SE and a similar risk of MB; in our study, we found that dabigatran was associated with a lower risk of both stroke/SE and MB.¹⁸ In the ROCKET-AF trial

(Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), rivaroxaban was noninferior for both stroke/SE and MB compared with warfarin; a significantly lower risk of stroke/SE was found for rivaroxaban versus warfarin in our study, and the difference in MB between rivaroxaban and warfarin reached statistical significance (with higher bleeding risk associated with rivaroxaban).¹⁹ The findings from this study may help inform the discussion of benefit and risk in the shared decision-making process for stroke prevention between healthcare providers and individual NVAf patients, when considering the balance between thromboembolic and bleeding risks.²¹

Table 1. Continued

Warfarin (N=83 007)	Apixaban (N=27 096)	Dabigatran (N=27 096)	Apixaban (N=62 619)	Rivaroxaban (N=62 619)	Dabigatran (N=27 538)	Rivaroxaban (N=27 538)
Mean/%	Mean/%	Mean/%	Mean/%	Mean/%	Mean/%	Mean/%
74.4	71.7	71.6	73.1	72.9	71.4	71.4
15.1%	24.9%	24.8%	22.3%	22.3%	25.4%	25.5%
33.6%	32.8%	32.8%	29.8%	30.3%	32.7%	32.3%
19.4%	17.4%	17.6%	17.1%	16.8%	17.4%	17.8%
31.9%	24.9%	24.8%	30.7%	30.6%	24.5%	24.4%
55.1%	59.3%	59.1%	55.2%	54.8%	59.5%	59.8%
44.9%	40.7%	40.9%	44.8%	45.2%	40.5%	40.2%
3.7	3.3	3.3	3.5	3.5	3.3	3.3
2.8%	5.9%	5.8%	4.5%	4.6%	6.0%	5.9%
5.6%	9.7%	9.6%	8.0%	8.5%	9.8%	10.1%
13.9%	17.3%	16.8%	15.8%	15.8%	17.0%	17.2%
23.5%	22.1%	22.2%	21.3%	21.2%	22.1%	21.7%
54.1%	45.0%	45.6%	50.5%	50.0%	45.1%	45.1%
2.9	2.6	2.7	2.9	2.8	2.6	2.6
2.5%	4.7%	4.6%	3.4%	3.5%	4.9%	4.9%
10.4%	14.6%	14.4%	12.4%	12.7%	14.7%	14.8%
27.3%	29.3%	29.2%	26.0%	26.3%	29.2%	27.9%
59.8%	51.4%	51.7%	58.2%	57.5%	51.2%	52.4%
27.9%	23.6%	24.1%	26.6%	26.1%	23.9%	23.9%
35.7%	33.6%	34.2%	33.5%	32.9%	34.4%	34.7%
20.6%	16.1%	16.0%	20.9%	20.8%	15.8%	15.9%
11.9%	9.7%	9.9%	11.2%	11.0%	9.8%	10.0%
19.5%	15.6%	15.5%	18.1%	18.4%	15.3%	16.2%
44.1%	39.7%	40.1%	44.6%	43.5%	39.8%	39.8%
	83.2%	84.8%	79.3%	73.3%	85.0%	76.7%
	16.8%	15.2%	20.7%	26.7%	15.0%	23.3%
250.5	198.9	235.5	198.6	240.1	234.6	241.2
160	133	130	133	149	128	149

HAS-BLED indicates hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs and alcohol; INR, international normalized ratio; and NOAC, non-vitamin K antagonists oral anticoagulants.

*As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0–8.

†Standard dose: 5 mg Apixaban, 150 mg Dabigatran, 20 mg Rivaroxaban.

‡Lower dose: 2.5 mg Apixaban, 75 mg Dabigatran, 10 or 15 mg Rivaroxaban. 4510; 3239; and 1350 patients in rivaroxaban-warfarin, apixaban-rivaroxaban, and dabigatran-rivaroxaban cohorts received 10 mg rivaroxaban, respectively.

Other retrospective observational studies comparing NOACs to warfarin have also been conducted using various US data sources.^{11,22–28} Systematic reviews and meta-analyses concluded that the comparative effectiveness and safety results in the real-world studies are generally consistent with those in the RCTs: all the NOACs were associated with similar or lower rates of stroke/SE and lower intracranial hemorrhage; apixaban was associated with lower rates of MB and gastrointestinal bleeding; dabigatran was associated with similar or lower rates of MB but similar or

higher rates of gastrointestinal bleeding; and rivaroxaban was associated with similar rates of MB and similar or higher gastrointestinal bleeding compared with warfarin.^{29–33} Our findings are generally consistent with these results.

Using the large pooled ARISTOPHANES data set with more statistical power and improved generalizability compared with previous literature, most of which used a single data source, this study showed consistent comparative effectiveness and safety results between NOACs and warfarin with




Figure 1. Kaplan-Meier curves for stroke/SE and major bleeding. **A**, Cumulative incidence of stroke/systemic embolism (SE) and major bleeding in non-vitamin K antagonist oral anticoagulant (NOAC)-warfarin propensity score-matched cohorts. **B**, Cumulative incidence of Stroke/SE and major bleeding in NOAC-NOAC propensity score-matched cohorts.




Figure 2. Comparison of stroke/SE and major bleeding between OACs. **A**, Incidence rates and hazard ratios of stroke/systemic embolism (SE) and major bleeding for non-vitamin K antagonist oral anticoagulants (NOACs) vs warfarin propensity score-matched cohorts. **B**, Incidence rates and hazard ratios of stroke/SE and major bleeding for NOACs vs NOACs propensity score-matched cohorts. GI indicates gastrointestinal; and ICH, intracranial hemorrhage.

previous studies. For example, this analysis had more statistical power in evaluating less frequent events (eg, intracranial hemorrhage) and subgroups with limited sample size in RCTs (eg, peripheral arterial disease). Indeed, our subgroup analyses provide supplemental information of the comparative effectiveness and safety among OACs stratifying by patient's

demographics, risk scores, and comorbidities, which showed generally consistent results with the main analysis.

Limitations

This retrospective observational study has several limitations. First, our study is subject to the inherent limitations

A									
Stroke/SE		Apixaban vs. Warfarin		Dabigatran vs. Warfarin		Rivaroxaban vs. Warfarin			
Subgroup	No. of events (incidence rate - per 100 person-years)	HR (95% CI)	No. of events (incidence rate - per 100 person-years)	HR (95% CI)	No. of events (incidence rate - per 100 person-years)	HR (95% CI)	No. of events (incidence rate - per 100 person-years)	HR (95% CI)	
Age, years									
<65	50 (1.07) vs. 73 (1.35)	0.76 (0.53-1.08)*	30 (0.92) vs. 41 (1.22)	0.76 (0.47-1.22)	79 (1.18) vs. 98 (1.47)	0.81 (0.60-1.09)			
65-74	121 (1.21) vs. 187 (1.47)	0.76 (0.61-0.96)*	62 (1.02) vs. 93 (1.44)	0.71 (0.51-0.98)	207 (1.05) vs. 283 (1.43)	0.74 (0.62-0.88)			
75-79	69 (1.10) vs. 157 (2.02)	0.51 (0.38-0.68)*	62 (1.79) vs. 67 (1.84)	0.98 (0.69-1.38)	158 (1.33) vs. 216 (1.80)	0.74 (0.61-0.91)			
≥80	198 (1.77) vs. 403 (2.98)	0.55 (0.47-0.65)*	105 (2.22) vs. 137 (2.89)	0.77 (0.60-0.99)	405 (2.20) vs. 548 (2.91)	0.76 (0.66-0.86)			
Gender									
Male	216 (1.28) vs. 375 (1.82)	0.66 (0.56-0.78)	123 (1.24) vs. 167 (1.61)	0.77 (0.61-0.97)	396 (1.31) vs. 536 (1.75)	0.75 (0.66-0.86)			
Female	222 (1.45) vs. 445 (2.36)	0.57 (0.49-0.67)	136 (1.78) vs. 171 (2.17)	0.82 (0.66-1.03)	453 (1.71) vs. 609 (2.28)	0.75 (0.66-0.85)			
CHA ₂ DS ₂ -VASC Score									
0-1	15 (0.59) vs. 14 (0.47)	1.18 (0.57-2.44)	9 (0.49) vs. 13 (0.65)	0.74 (0.32-1.72)	17 (0.43) vs. 19 (0.50)	0.86 (0.45-1.65)			
2-3	77 (0.65) vs. 160 (1.13)	0.54 (0.41-0.71)	59 (0.84) vs. 63 (0.87)	0.97 (0.68-1.38)	171 (0.79) vs. 240 (1.12)	0.72 (0.59-0.87)			
≥4	346 (1.95) vs. 646 (2.90)	0.62 (0.55-0.71)	191 (2.20) vs. 262 (2.92)	0.76 (0.63-0.91)	661 (2.11) vs. 886 (2.76)	0.77 (0.69-0.85)			
HAS-BLED Score									
<3	79 (0.65) vs. 162 (1.07)	0.57 (0.43-0.74)	62 (0.78) vs. 86 (1.03)	0.75 (0.54-1.04)	172 (0.77) vs. 270 (1.19)	0.65 (0.54-0.79)*			
≥3	359 (1.80) vs. 658 (2.71)	0.62 (0.54-0.70)	197 (2.06) vs. 252 (2.54)	0.81 (0.68-0.98)	677 (1.97) vs. 875 (2.53)	0.78 (0.71-0.86)*			
CHF									
No	259 (1.10) vs. 510 (1.77)	0.58 (0.50-0.67)	164 (1.22) vs. 227 (1.62)	0.75 (0.61-0.92)	560 (1.33) vs. 753 (1.77)	0.75 (0.67-0.84)			
Yes	179 (2.10) vs. 310 (2.92)	0.67 (0.56-0.81)	95 (2.34) vs. 111 (2.63)	0.89 (0.68-1.17)	289 (2.00) vs. 392 (2.66)	0.75 (0.65-0.88)			
CAD									
No	177 (1.01) vs. 387 (1.78)	0.53 (0.44-0.64)*	116 (1.11) vs. 181 (1.64)	0.68 (0.54-0.85)*	409 (1.27) vs. 557 (1.71)	0.75 (0.66-0.85)			
Yes	261 (1.78) vs. 433 (2.44)	0.68 (0.58-0.79)*	143 (2.02) vs. 157 (2.19)	0.93 (0.74-1.16)*	440 (1.79) vs. 588 (2.37)	0.76 (0.67-0.86)			
PAD									
No	309 (1.18) vs. 550 (1.73)	0.64 (0.55-0.73)	194 (1.31) vs. 236 (1.56)	0.84 (0.70-1.02)	610 (1.31) vs. 788 (1.69)	0.78 (0.70-0.87)			
Yes	129 (2.16) vs. 270 (3.51)	0.58 (0.47-0.71)	65 (2.42) vs. 102 (3.35)	0.72 (0.53-0.99)	239 (2.32) vs. 357 (3.31)	0.70 (0.60-0.83)			
Renal Disease									
No	277 (1.09) vs. 538 (1.74)	0.59 (0.51-0.68)	198 (1.33) vs. 238 (1.54)	0.87 (0.72-1.05)*	593 (1.28) vs. 801 (1.72)	0.75 (0.67-0.83)			
Yes	161 (2.37) vs. 282 (3.33)	0.66 (0.55-0.81)	61 (2.27) vs. 100 (3.59)	0.62 (0.45-0.86)*	256 (2.46) vs. 344 (3.17)	0.77 (0.66-0.91)			
Diabetes									
No	227 (1.07) vs. 478 (1.85)	0.54 (0.46-0.63)*	146 (1.27) vs. 184 (1.56)	0.82 (0.66-1.02)	466 (1.26) vs. 667 (1.80)	0.70 (0.62-0.79)*			
Yes	211 (1.93) vs. 342 (2.52)	0.71 (0.60-0.85)*	113 (1.87) vs. 154 (2.39)	0.78 (0.61-0.99)	383 (1.94) vs. 478 (2.34)	0.82 (0.72-0.94)*			
Prior Stroke/SE									
No	250 (0.88) vs. 498 (1.44)	0.57 (0.49-0.67)*	177 (1.13) vs. 211 (1.30)	0.87 (0.71-1.06)	545 (1.09) vs. 715 (1.41)	0.77 (0.69-0.86)			
Yes	188 (4.96) vs. 322 (6.68)	0.67 (0.56-0.81)*	82 (4.35) vs. 127 (6.46)	0.68 (0.51-0.89)	304 (4.50) vs. 430 (6.31)	0.72 (0.62-0.83)			
Dose									
Lower Dose	130 (1.85) vs. 238 (2.76)	0.62 (0.50-0.77)	73 (2.74) vs. 61 (2.20)	1.30 (0.92-1.82)*	316 (2.12) vs. 387 (2.40)	0.87 (0.75-1.01)			
Standard Dose	268 (1.19) vs. 452 (1.61)	0.68 (0.59-0.80)	166 (1.23) vs. 203 (1.43)	0.85 (0.70-1.05)	473 (1.20) vs. 621 (1.59)	0.76 (0.67-0.86)			
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4									
B									
Major Bleeding		Apixaban vs. Warfarin		Dabigatran vs. Warfarin		Rivaroxaban vs. Warfarin			
Subgroup	No. of events (incidence rate - per 100 person-years)	HR (95% CI)	No. of events (incidence rate - per 100 person-years)	HR (95% CI)	No. of events (incidence rate - per 100 person-years)	HR (95% CI)	No. of events (incidence rate - per 100 person-years)	HR (95% CI)	
Age, years									
<65	81 (1.73) vs. 187 (3.47)	0.48 (0.37-0.62)	39 (1.20) vs. 106 (3.15)	0.38 (0.26-0.55)*	150 (2.24) vs. 245 (3.68)	0.62 (0.50-0.76)*			
65-74	294 (2.95) vs. 614 (4.85)	0.56 (0.49-0.65)	167 (2.75) vs. 285 (4.44)	0.62 (0.51-0.75)*	835 (4.27) vs. 904 (4.59)	0.93 (0.85-1.03)*			
75-79	224 (3.60) vs. 472 (6.14)	0.55 (0.47-0.64)	118 (3.41) vs. 188 (5.21)	0.66 (0.52-0.83)*	693 (5.90) vs. 654 (5.50)	1.08 (0.97-1.20)*			
≥80	546 (4.90) vs. 1,009 (7.55)	0.61 (0.55-0.67)	300 (6.38) vs. 308 (6.56)	0.98 (0.83-1.14)*	1,557 (8.57) vs. 1,260 (6.75)	1.27 (1.18-1.37)*			
Gender									
Male	557 (3.32) vs. 1,149 (5.63)	0.55 (0.50-0.61)	308 (3.12) vs. 486 (4.73)	0.66 (0.57-0.76)*	1,512 (5.06) vs. 1,556 (5.11)	0.99 (0.92-1.07)*			
Female	588 (3.87) vs. 1,133 (6.06)	0.60 (0.54-0.66)	316 (4.15) vs. 401 (5.13)	0.81 (0.70-0.94)*	1,723 (6.55) vs. 1,507 (5.70)	1.16 (1.08-1.24)*			
CHA ₂ DS ₂ -VASC Score									
0-1	28 (1.11) vs. 58 (1.96)	0.53 (0.34-0.84)	11 (0.60) vs. 47 (2.36)	0.25 (0.13-0.48)*	54 (1.38) vs. 73 (1.94)	0.71 (0.50-1.01)*			
2-3	237 (2.01) vs. 533 (3.77)	0.50 (0.43-0.58)	152 (2.17) vs. 242 (3.35)	0.65 (0.53-0.79)*	699 (3.27) vs. 768 (3.60)	0.92 (0.83-1.02)*			
≥4	880 (4.98) vs. 1,691 (7.68)	0.60 (0.56-0.66)	461 (5.33) vs. 598 (6.73)	0.80 (0.71-0.90)*	2,482 (8.04) vs. 2,222 (6.99)	1.15 (1.09-1.22)*			
HAS-BLED Score									
<3	193 (1.59) vs. 417 (2.76)	0.54 (0.46-0.64)*	144 (1.81) vs. 225 (2.71)	0.66 (0.54-0.82)	638 (2.86) vs. 633 (2.79)	1.03 (0.92-1.15)			
≥3	952 (4.80) vs. 1,865 (7.78)	0.58 (0.53-0.63)*	480 (5.04) vs. 662 (6.76)	0.75 (0.67-0.84)	2,597 (7.67) vs. 2,430 (7.10)	1.08 (1.02-1.14)			
CHF									
No	580 (2.46) vs. 1,225 (4.27)	0.54 (0.49-0.60)	334 (2.48) vs. 510 (3.66)	0.68 (0.59-0.78)	1,800 (4.29) vs. 1,725 (4.07)	1.06 (0.99-1.13)			
Yes	565 (6.70) vs. 1,057 (10.14)	0.62 (0.56-0.69)	290 (7.18) vs. 377 (9.07)	0.80 (0.68-0.93)	1,435 (10.08) vs. 1,338 (9.23)	1.10 (1.02-1.18)			
CAD									
No	428 (2.46) vs. 869 (4.01)	0.57 (0.51-0.65)	269 (2.58) vs. 388 (3.52)	0.73 (0.63-0.85)	1,331 (4.16) vs. 1,268 (3.91)	1.07 (0.99-1.15)			
Yes	717 (4.91) vs. 1,413 (8.10)	0.57 (0.52-0.62)	355 (5.03) vs. 499 (7.06)	0.72 (0.63-0.82)	1,904 (7.87) vs. 1,795 (7.34)	1.08 (1.01-1.15)			
PAD									
No	774 (2.97) vs. 1,520 (4.82)	0.58 (0.53-0.63)	453 (3.06) vs. 612 (4.06)	0.75 (0.67-0.85)	2,239 (4.86) vs. 2,109 (4.56)	1.07 (1.01-1.14)			
Yes	371 (6.28) vs. 762 (10.07)	0.59 (0.52-0.66)	171 (6.43) vs. 275 (9.16)	0.70 (0.58-0.85)	996 (9.83) vs. 954 (8.97)	1.10 (1.01-1.20)			
Renal Disease									
No	676 (2.68) vs. 1,290 (4.19)	0.60 (0.55-0.66)	409 (2.76) vs. 582 (3.79)	0.73 (0.65-0.83)*	2,129 (4.64) vs. 1,919 (4.15)	1.12 (1.06-1.19)*			
Yes	469 (6.94) vs. 992 (11.98)	0.55 (0.49-0.61)	215 (8.06) vs. 305 (11.15)	0.71 (0.60-0.85)*	1,106 (10.81) vs. 1,144 (10.75)	1.01 (0.93-1.09)*			
Diabetes									
No	619 (2.93) vs. 1,249 (4.86)	0.57 (0.51-0.62)*	341 (2.98) vs. 491 (4.20)	0.71 (0.62-0.82)	1,833 (5.01) vs. 1,674 (4.56)	1.11 (1.04-1.18)			
Yes	526 (4.84) vs. 1,033 (7.70)	0.59 (0.53-0.65)*	283 (4.70) vs. 396 (6.19)	0.75 (0.65-0.88)	1,402 (7.17) vs. 1,389 (6.89)	1.04 (0.96-1.12)			
Prior Stroke/SE									
No	909 (3.22) vs. 1,864 (5.44)	0.56 (0.51-0.60)	516 (3.31) vs. 743 (4.61)	0.72 (0.64-0.80)	2,641 (5.34) vs. 2,526 (5.04)	1.06 (1.01-1.12)			
Yes	236 (6.22) vs. 418 (8.70)	0.64 (0.55-0.76)	108 (5.71) vs. 144 (7.29)	0.79 (0.61-1.01)	594 (8.87) vs. 537 (7.87)	1.14 (1.01-1.28)			
Dose									
Lower Dose	348 (4.97) vs. 695 (8.16)	0.57 (0.50-0.65)	174 (6.53) vs. 215 (7.86)	0.89 (0.73-1.09)*	1,206 (8.17) vs. 1,160 (7.28)	1.11 (1.02-1.20)			
Standard Dose	725 (3.23) vs. 1,310 (4.70)	0.64 (0.59-0.70)	424 (3.16) vs. 619 (4.39)	0.72 (0.63-0.81)	1,896 (4.85) vs. 1,707 (4.40)	1.11 (1.04-1.18)			
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4									

Figure 3. Subgroup analysis. **A**, Propensity score-matched hazard ratios of stroke/systemic embolism (SE) for non-vitamin K antagonist oral anticoagulant (NOAC)-warfarin comparisons. †Age was included in the model because it was not balanced after propensity score matching (PSM) for apixaban and warfarin patients with prior stroke and for dabigatran and warfarin patients with renal disease. ‡Charlson Comorbidity Index (CCI) and anemia and coagulation defects were included in the model because they were not balanced after PSM between 75 mg dabigatran and warfarin patients. **B**, Propensity score-matched hazard ratios of major bleeding for NOAC-warfarin comparisons. †Age was included in the model because it was not balanced after PSM for apixaban and warfarin patients with prior stroke and for dabigatran and warfarin patients with renal disease. ‡CCI and anemia and coagulation defects were included in the model because they were not balanced after PSM between 75 mg dabigatran and warfarin patients. (Continued)




Figure 3 Continued. C, Propensity score-matched hazard ratios of stroke/SE for NOAC-NOAC comparisons. **D,** Propensity score-matched hazard ratios of major bleeding for NOAC-NOAC comparisons. *Significant interactions were found (whether treatment effect was statistically different across subgroups). CAD indicates coronary artery disease; CHF, congestive heart failure; HAS-BLED, hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs and alcohol; and PAD, peripheral artery disease.

of retrospective evaluations using healthcare claims data. Only statistical association rather than causal relationships could be concluded. Although cohorts were matched through PSM, potential residual confounders exist. In clinical practice, patients who receive different OACs may be systematically different, and to the extent that such differences are unobserved, study results may be biased. Other unmeasurable factors including differences in physician-level, practice-level, and health plan-level characteristics may also confound the estimated association between medication exposure (individual OAC) and outcomes (stroke/SE and MB). This limitation is especially important for interpreting NOAC versus NOAC comparison results, which are for hypothesis generation given the lack of head-to-head trials. From an exploratory power calculation conducted by authors based on indirect treatment comparison of pivotal RCTs, nearly 27 000 patients would be needed to evaluate stroke/SE and MB outcomes across the 3 NOACs in a hypothetical head-to-head trial (assuming a 90% power). Second, because of the nature of claims studies, outcome measures were based on *International Classification of Diseases, Ninth Revision, Clinical Modification* codes without further adjudication using precise clinical criteria or further validation against healthcare providers' medical records. No evaluation of the dose reduction criteria for NOACs was allowed without comprehensive data on body weight or serum creatinine/creatinine clearance. In addition, laboratory values, such as international normalized ratio measurements, are not available in the data set so we are unable to determine time in therapeutic range for patients prescribed warfarin. Nonetheless, by including patients with potentially poorer quality control of warfarin in everyday clinical practice, the findings of this study may better reflect real-world situations. Many clinically important outcomes (eg, mild to moderate bleeding) associated with OAC use were not evaluated in the study because they cannot be reliably measured in claims databases. We relied on prescription dispense records to characterize OAC drug

exposure, but patients' actual drug taking behaviors cannot be measured. Observed and unobserved heterogeneity may exist across the 5 data sources. However, published NOAC studies using those data sources have reported generally consistent findings.^{11,24,27,28} Finally, the results may not be generalizable to the overall NVAF population in the United States because the study did not include uninsured patients and patients solely covered by other public health insurance plans.

Some literature has proposed hypotheses on potential differences in clinical outcomes between patients with different NOAC treatment based on existing pharmacological differences across NOACs (Table 2). A pharmacokinetics and pharmacodynamics study suggested that once-daily dosing may potentially increase absolute patient adherence, but twice-daily dosing regimens may be more forgiving among patients with suboptimal adherence because of lower peak level and higher trough level of drug concentration.³⁴ Rivaroxaban should be taken together with an evening meal, as this increases bioavailability.^{35,36} In a recent US real-world study, about one-third of rivaroxaban users did not take rivaroxaban with an adequate meal.³⁷ Apixaban and dabigatran do not demonstrate the same degree of food effect. However, no study has formally tested the causal relationship between pharmacological difference and clinical outcomes.

Please note that our NOAC versus NOAC comparisons are for hypotheses generating only. Those results should be interpreted with caution and need to be confirmed by findings from NOAC versus NOAC RCTs which are expected to be released in the upcoming years (eg, DARING-AF trial [Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation; URL: <https://www.clinicaltrials.gov>. Unique identifier: NCT02666157] in Taiwan and DANNOAC-AF trial [The Danish Non-Vitamin K Antagonist Oral Anticoagulation Study: A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for

Table 2. Clinical Pharmacology of Oral Anticoagulants

	Warfarin	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Mechanism of action	Inhibitor of vitamin K-dependent factors	Direct thrombin inhibitor	Direct factor Xa inhibitor	Direct factor Xa inhibitor	Direct factor Xa inhibitor
Oral bioavailability	>95%	≈6.5%	80%–100%	≈50%	≈62%
Pro-drug	No	Yes	No	No	No
Food effect	Yes (foods high in vitamin K)	No	Yes (20 mg and 15 mg doses need to be taken with food)	No	No
Renal clearance	Metabolized in liver, and excreted in urine mainly as metabolites	85%	≈33%*	≈27%	50%
Mean half-life ($t_{1/2}$)	40 h	14–18 h†	5–9 h (young) 11–13 h (elderly)	12 h	10–14 h
T_{max}	72–96 h	0.5–2 h	2–4 h	3–4 h	1–2 h

OACs indicates oral anticoagulants; PI, prescribing information; and T_{max} , time to reach peak plasma concentration.

*Direct renal excretion as unchanged active substance.

†Prolonged in patients with impaired renal function, licensed for patients up to moderate renal impairment.

Oral Anticoagulation in Atrial Fibrillation; URL: <https://www.clinicaltrials.gov>. Unique identifier: NCT03129490] in Denmark).^{38,39}

Conclusions

In the largest observational study of NOAC use to date, we show that NOACs had lower rates of stroke/SE and variable comparative rates of MB versus warfarin. A comprehensive set of subgroup analyses in this study provide further evidence in the important subgroups of NVAF patients.

Sources of Funding

This study was funded by Pfizer Inc and Bristol-Myers Squibb.

Disclosures

A. Keshishian is a paid employee of STATinMED Research which is a paid consultant to Pfizer and Bristol-Myers Squibb. Dr Li, M. Hamilton, Dr Gupta, K. Friend, X. Pan, and Dr Nadkarni are paid employees of Bristol-Myers Squibb with ownership of stocks in Bristol-Myers Squibb. Drs Masseria, Luo, and Mardekian are paid employees of Pfizer Inc with ownership of stocks in Pfizer Inc. Dr Lip is a consultant for Bayer/Janssen, Merck, Sanofi, Bristol-Myers Squibb Company/Pfizer Inc, Daiichi-Sankyo, Biotronik, Medtronic, Portola, Novartis, Verseon, and Boehringer Ingelheim and has been on the speakers' bureau for Bayer, Bristol-Myers Squibb Company/Pfizer Inc, Boehringer Ingelheim, Daiichi-Sankyo, and Medtronic. Dr Deitelzweig is a consultant for Bayer/Janssen, Bristol-Myers Squibb Company/Pfizer Inc, Daiichi-Sankyo, Portola, and Boehringer Ingelheim and has been on the speakers' bureau for Janssen, Bristol-Myers Squibb Company/Pfizer Inc, and Boehringer Ingelheim. Dr Lip, A. Keshishian, Dr Li, M. Hamilton, Dr Masseria, Dr Gupta, Dr Luo, Dr Friend, Dr Nadkarni, and Dr Deitelzweig contributed to conceptualize or design the work. A. Keshishian, Dr Li, X. Pan, and Dr Baser contributed to acquire the data for the work. A. Keshishian, Dr Mardekian, and X. Pan contributed to analyze the data for the work. All authors contributed to interpret the data for the work. A. Keshishian, Dr Li, Dr Luo, and Dr Friend drafted the work. All authors critically revised for important intellectual content. All authors finally approved the version to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

1. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. *Thromb Haemost*. 2017;117:1230–1239. doi: 10.1160/TH16-11-0876
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007;146:857–867.
3. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. *Thromb Haemost*. 2013;110:1087–1107. doi: 10.1160/TH13-06-0443
4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014;383:955–962. doi: 10.1016/S0140-6736(13)62343-0
5. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. *J Thromb Thrombolysis*. 2011;31:326–343. doi: 10.1007/s11239-011-0561-1
6. Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, et al; GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF

- Phase II Registry. *Thromb Haemost*. 2017;117:2376–2388. doi: 10.1160/TH17-08-0555
7. Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, et al. Systematic review and network meta-analysis comparing anti-thrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. *BMJ Open*. 2014;4:e004301. doi: 10.1136/bmjopen-2013-004301
8. López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. *BMJ*. 2017;359:j5058.
9. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. *Chest*. 2016;150:1302–1312. doi: 10.1016/j.chest.2016.07.013
10. Graham DJ, Reichman ME, Werneck M, Hsueh YH, Izem R, Southworth MR, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for non-valvular atrial fibrillation. *JAMA Intern Med*. 2016;176:1662–1671. doi: 10.1001/jamainternmed.2016.5954
11. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. *Thromb Haemost*. 2017;117:1072–1082. doi: 10.1160/TH17-01-0068
12. Thigpen JL, Dillon C, Forster KB, Henault L, Quinn EK, Tripodis Y, et al. Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2015;8:8–14. doi: 10.1161/CIRCOUTCOMES.113.000371
13. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. *Pharmacoepidemiol Drug Saf*. 2011;20:560–566. doi: 10.1002/pds.2109
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40:373–383.
15. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat Med*. 2014;33:1242–1258. doi: 10.1002/sim.5984
16. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med*. 2009;28:3083–3107. doi: 10.1002/sim.3697
17. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210
18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361:1139–1151. doi: 10.1056/NEJMoa0905561
19. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. *N Engl J Med*. 2011;365:883–891. doi: 10.1056/NEJMoa1009638
20. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011;365:981–992. doi: 10.1056/NEJMoa1107039
21. Nielsen PB, Skjøth F. A two-sided evaluation of benefit and harm from antithrombotic treatment in atrial fibrillation: balancing clinical application and statistical methodology. *Thromb Haemost*. 2016;116:405–406. doi: 10.1160/TH16-07-0523
22. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. *J Am Heart Assoc*. 2016;5:e003725.
23. Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. *Thromb Haemost*. 2015;114:1290–1298. doi: 10.1160/TH15-06-0453
24. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States

- Medicare population. *Curr Med Res Opin.* 2017;33:1595–1604. doi: 10.1080/03007995.2017.1345729
25. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. *Am J Cardiol.* 2017;120:1813–1819. doi: 10.1016/j.amjcard.2017.07.092
 26. Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. *Curr Med Res Opin.* 2016;32:2047–2053. doi: 10.1080/03007995.2016.1237937
 27. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. *Thromb Haemost.* 2015;114:1277–1289. doi: 10.1160/TH15-06-0497
 28. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation.* 2015;131:157–164. doi: 10.1161/CIRCULATIONAHA.114.012061
 29. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. *Stroke.* 2017;48:2494–2503. doi: 10.1161/STROKEAHA.117.017549
 30. Deitelzweig S, Farmer C, Luo X, Vo L, Li X, Hamilton M, et al. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. *Curr Med Res Opin.* 2017;33:1583–1594. doi: 10.1080/03007995.2017.1347090
 31. Bai Y, Shi XB, Ma CS, Lip GYH. Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban. *Am J Cardiol.* 2017;120:1689–1695. doi: 10.1016/j.amjcard.2017.07.072
 32. Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. *Stroke.* 2017;48:970–976. doi: 10.1161/STROKEAHA.116.016275
 33. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. *Thromb Haemost.* 2016;116:754–763. doi: 10.1160/TH16-03-0203
 34. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. *Europace.* 2015;17:514–523. doi: 10.1093/europace/euu311
 35. Stampfuss J, Kubitz D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. *Int J Clin Pharmacol Ther.* 2013;51:549–561. doi: 10.5414/CP201812
 36. Rivaroxaban- Food and Drug Administration, Prescribing Information. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022406s009lbl.pdf. Accessed May 8, 2018.
 37. Packard KA, Leiter M, Qi Y, et al. Evaluation of rivaroxaban administration for atrial fibrillation in a cardiology practice. *JACC.* 2018;17:333.
 38. Tainan Municipal Hospital, E-DA Hospital, National Cheng-Kung University Hospital Dou-Liou Branch, Ministry of Health and Welfare, Taiwan. Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, Apixaban, Non-Valvular Atrial Fibrillation (DARING-AF). 2016. <https://clinicaltrials.gov/ct2/show/NCT02666157>. Accessed July 25, 2018.
 39. Danish Heart Foundation. Danish Society of Cardiology. The Danish Non-Vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (DANNOAC-AF). 2017. <https://clinicaltrials.gov/ct2/show/NCT03129490>. Accessed July 25, 2018.